Business
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be
About this update from Viatris Inc.
[{"type":"text","content":"Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated\nData shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod\nPITTSBURGH, Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress. The congress is being held August 21-25, 2024, in Suntec, Singapore.\nThe ACT-333441 study was a randomized, double-blind, parallel-group, multicenter, Phase 2 study that was conducted in Japan and evaluated the safety, pharmacodynamics (PD), and efficacy of cenerimod, a selective S1P1 receptor modulator, in 17 Japanese patients with moderate to severe systemic lupus erythematosus (SLE). Adult patients receiving SLE background treatment were randomized equally to either 2 mg or 4 mg cenerimod (once-daily, oral dosing). The primary endpoint of the study measured safety and tolerability, and the secondary endpoint measured a change in total lymphocyte count and the efficacy was assessed using a modified SLEDAI-2K (mSLEDAI-2K) score.\nBoth cenerimod doses were considered safe and well-tolerated. A decrease in lymphocyte counts was observed in both the 2 mg and 4 mg doses as expected per the mechanism of action of cenerimod and was reversible upon treatment discontinuation. Both doses showed a clinically meaningful improvement in disease activity, as measured by mSLEDAI-2K, which persisted long after the treatment was discontinued and was higher with the 4 mg dose. These results are generally consistent with the global Phase 2 CARE study*.\nVisit Viatris at APLAR at Booth #21-23 to learn more about the study and how the company continues to support the needs of the SLE community. The data was presented during the following oral presentation:\nCenerimod in Japanese patients with moderate to severe systemic lupus erythematosus (SLE): A Phase 2, randomized, double-blind trialSpeaker: Sharavan KanagaratnamAugust 23, 3:00 - 4:15 p.m. GM...